Story
Jazz Pharmaceuticals Stock Hits Record High on FDA Approval for Cancer Drug Ziihera

Shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) climbed 2.3% in afternoon trading Tuesday, reaching a new all-time high after the U.S. Food and Drug Administration (FDA) approved its cancer therapy, Ziihera (zanidatamab-hrii).
FDA Greenlights New Cancer Therapy
The FDA granted approval for two Ziihera-containing combination regimens as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, a type of stomach or esophageal cancer. The agency's decision arrived on its PDUFA (Prescription Drug User Fee Act) target action date of August 25, 2026.
The approval covers two distinct treatment approaches:
- A triplet regimen of Ziihera combined with Tevimbra (tislelizumab-jsgr) and chemotherapy.
- A doublet regimen of Ziihera combined with chemotherapy alone.
Market Reaction and Outlook
AdThe positive regulatory news acted as a significant catalyst for the stock, pushing it to an intraday and all-time high of $266.38. The approval reinforces growing investor confidence, which had been building following a strong second-quarter 2026 earnings report where Jazz posted revenue of $1.21 billion, surpassing consensus estimates.
Analyst sentiment has been positive, with multiple Wall Street firms raising their price targets on the company ahead of the decision. Current price targets from major analysts range from $264 to $310, reflecting optimism about the company's diversified neuroscience and oncology pipeline.
Broader Context
The approval also had a positive impact on Jazz's partners, including BeOne Medicines and Zymeworks, the originator of the zanidatamab molecule. The broader market provided a modest tailwind, with the S&P 500 up approximately 0.3% on the day.
Overall, the combination of a significant and long-awaited FDA approval, a strong recent financial performance, and supportive analyst ratings converged to drive the stock to record levels, underscoring the market's validation of Jazz Pharmaceuticals' oncology growth strategy.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.